UBS Group
ENGNW icon

UBS Group’s enGene Therapeutics Warrants ENGNW Stock Holding History

UBS Group’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,706
Closed -$4.76K – 10669
2025
Q3 		$4.76K Sell
6,706
-12,958
-66% -$9.82K ﹤0.01% 8926
2025
Q2 		$16.1K Sell
19,664
-2,269
-10% -$1.58K ﹤0.01% 8581
2025
Q1 		$13.2K Buy
21,933
+19,106
+676% +$15.7K ﹤0.01% 8470
2024
Q4 		$2.38K Sell
2,827
-381
-12% -$562 ﹤0.01% 9055
2024
Q3 		$2.76K Sell
3,208
-8,952
-74% -$10.6K ﹤0.01% 8372
2024
Q2 		$14.5K Buy
+12,160
New +$38.9K ﹤0.01% 7512

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

UBS Group's ENGNW Position: Q4 2025 in Review

UBS Group sold out of enGene Therapeutics Warrants (ENGNW) in Q4 2025, closing a stake of 6,706 shares — an estimated $4.76K sold.

UBS Group first reported a position in ENGNW in Q2 2024 and held it in 6 quarters. The position peaked at $16.1K in Q2 2025. 14 funds tracked by Wall St. Rank hold ENGNW as of Q4 2025.

  • UBS Group reported no remaining enGene Therapeutics Warrants position as of Q4 2025 after selling out during the quarter.
  • UBS Group sold 6,706 enGene Therapeutics Warrants shares in Q4 2025, an estimated $4.76K.
  • UBS Group first reported a position in enGene Therapeutics Warrants in Q2 2024 and held it in 6 quarters.
  • UBS Group's enGene Therapeutics Warrants position peaked at $16.1K in Q2 2025.
  • 14 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.